This article is more than 5 years old. Information may no longer be current.
Cardiology Today's Top 5 articles posted in February
Click Here to Manage Email Alerts
Cardiology Today compiled a list of the top 5 stories posted to Healio.com/Cardiology in February.
This month, Cardiology Today’s readers were most interested in screenings for women to detect heart disease, the efficacy of rivaroxaban (Xarelto, Janssen Pharmaceuticals) in treating CV events in patients with CAD and peripheral artery disease, the results of the FOURIER trial, the risks vs. benefits of statin therapy, the suspension of the injunction preventing the sale of alirocumab (Repatha, Sanofi/Regeneron) in the United States, and much more.
Survey: Most women unaware that screening for heart disease should start early
A survey commissioned by Orlando Health found that few women knew that simple screenings to detect risk for heart disease should begin at age 20 years.
COMPASS: Rivaroxaban superior to aspirin for prevention of CV events in patients with CAD, PAD
Janssen Pharmaceuticals announced that the COMPASS trial of rivaroxaban for prevention of major adverse CV events in patients with CAD or PAD was stopped early due to superiority being demonstrated.
FOURIER: Evolocumab reduces risk for CV events in atherosclerotic CVD
Amgen announced that FOURIER, the CV outcomes trial of its PCSK9 inhibitor evolocumab (Repatha), met its primary endpoint and key secondary endpoint.
Benefits of statin therapy outweigh diabetes risk
In a commentary published in The American Journal of Medicine, experts wrote that the CV benefits of statins outweigh any diabetes-related risk they may present.
Alirocumab allowed to remain on U.S. market pending completion of appeal
Regeneron Pharmaceuticals and Sanofi announced that the United States Court of Appeals for the Federal Circuit has suspended the permanent injunction preventing the U.S. sale and manufacturing of their PCSK9 inhibitor alirocumab pending the companies' appeal.